SCHEMBL22487791

SCHEMBL22487791

CCN1Cc2[nH]c3ccc(OCc4ccccc4)cc3c2C(=O)N(C)C1=O

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOB P27338 8/20 0.52
MAOA P21397 7/20 0.52
CTSV O60911 3/20 0.45
CTSL P07711 3/20 0.45
ACHE P22303 1/20 0.43
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TRPM8 Q7Z2W7 1/20 0.42
GABRA1 P14867 1/20 0.42
GABRG2 P18507 1/20 0.42
GABRB3 P28472 1/20 0.42
GABRA5 P31644 1/20 0.42
GABRA3 P34903 1/20 0.42
GABRA2 P47869 1/20 0.42
CHEK1 O14757 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19168811 0.84 KDR (0.46) ACHEMAPTKDM4ELMNAHPGD
SCHEMBL19167697 0.80 CYP1A2 (0.43) MAPTKDM4EHPGDHTTHSD17B10
SCHEMBL19167816 0.76 ALDH1A1 (0.41) MAPTKDM4EHPGDHSD17B10
SCHEMBL17500200 0.72 HDAC6 (0.55) MAOBMAOACTSVCTSLACHE
SCHEMBL22467817 0.72 HDAC6 (0.55) MAOBMAOACTSVCTSLACHE
SCHEMBL20634781 0.72 HDAC6 (0.55) MAOBMAOACTSVCTSLACHE
SCHEMBL9672176 0.71 MAOB (0.55) MAOBMAOACTSVCTSLKDM4E
SCHEMBL5097222 0.70 MAOA (0.57) MAOBMAOACTSVCTSLMAPT
SCHEMBL11869773 0.69 MAOB (1.00) MAOBMAOACTSVCTSLACHE
SCHEMBL20635509 0.69 MAOA (0.49) MAOBMAOACTSVCTSLACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11198694-B2 HDAC6 inhibitors, with improved solubility and their uses UNIVERSITÄT REGENSBURG (DE) 2021-12-14 US disclosed
US-20200308174-A1 NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES UNIVERSITÄT REGENSBURG (DE) 2020-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11198694-B2 HDAC6 inhibitors, with improved solubility and their uses HDAC6, HDAC1, HDAC5 MAOB 1586/4885MAOA 1777/4885CTSV 941/4885
US-20200308174-A1 NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES HDAC6, HDAC1, HDAC2 MAOB 1310/4885MAOA 1722/4885CTSV 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.